ライフサイエンスコーパス: intravitreal injection

1 vides opportunities for dosing routes beyond intravitreal injection.

2 sive or a dispersive OVD via intracameral or intravitreal injection.

3 d ranibizumab from the vitreous cavity after intravitreal injection.

4 ment with HORV 1 to 21 days after surgery or intravitreal injection.

5 mediate transduction following noninvasive, intravitreal injection.

6 d RGCs into uninjured rat retinas in vivo by intravitreal injection.

7 her countries using different techniques for intravitreal injections.

8 ve ranibizumab 0.5 mg or bevacizumab 1.25 mg intravitreal injections.

9 omplete resolution of fluid despite multiple intravitreal injections.

10 One patient underwent bilateral intravitreal injections.

11 utes, respectively, with subconjunctival and intravitreal injections.

12 uprachoroidal, posterior subconjunctival, or intravitreal injections.

13 All study treatments were given as intravitreal injections.

14 drug application in rabbits was achieved by intravitreal injections.

15 ntravitreal implants may supplant repetitive intravitreal injections.

16 ed, including prior occurrence and number of intravitreal injections.

17 rgoing cataract surgery after multiple prior intravitreal injections.

18 surgery for beneficiaries with a history of intravitreal injections.

19 d by anti-vascular endothelial growth factor intravitreal injections.

20 ncomycin via intracameral bolus (33/36), via intravitreal injection (1/36), or through the irrigation

21 ), post-glaucoma implant (6/19, 31.6%), post-intravitreal injection (2/19, 10.5%), endogenous endopht

22 d by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92

23 both at baseline (73%) and following serial intravitreal injections (78%, P = .73).

24 Fifteen thousand eight hundred ninety-five intravitreal injections (9453 ranibizumab, 5386 bevacizu

25 Intravitreal injections accounted for 0.55% of all vitre

26 rts were created using information on 530382 intravitreal injections administered from January 1, 200

27 ized to receive ranibizumab 0.5 mg or 2.0 mg intravitreal injections administered monthly or on a PRN

28 Mice were treated with carcinine (intravitreal injection and gavage) and exposed to bright

29 -up visits were performed 1 month after each intravitreal injection and included OCT analysis to eval

30 Conversely, both intravitreal injection and intraperitoneal injection of

31 was 100% regression of vitreous seeds after intravitreal injection and no eye was treated with radia

32 95% CI, 0.006-0.05) among those treated with intravitreal injections and 0.01 per EY (95% CI, 0.002-0

33 Given the frequency of intravitreal injections and cataract surgery, increased

34 of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment eff

35 rapies with potential include corticosteroid intravitreal injections and implants, and intravitreal a

36 he potential to reduce the risk from monthly intravitreal injections and the burden of monthly monito

37 rate of FFS Medicare beneficiaries receiving intravitreal injections and the mean Medicare-allowed dr

38 aract extraction, pars plana vitrectomy, and intravitreal injections and to check whether its treatme

39 ts received 4 consecutive monthly unilateral intravitreal injections and were then treated as needed.

40 each of the four groups at P17 (3 days after intravitreal injection) and the difference related to th

41 injections is granulomatous, seen only with intravitreal injections, and may result from either an a

42 lyses, the risk of endophthalmitis following intravitreal injections, and the fact that intravitreal

43 Repeat analysis considering intravitreal injections as a categoric variable showed 1

44 By considering the number of previous intravitreal injections as a continuous variable, the od

45 iltrate cells in the EAU mice after a single intravitreal injection at the onset of peak disease.

46 accept a high treatment burden with regular intravitreal injections at short intervals and long peri

47 s had received an average of 7 (range, 3-13) intravitreal injections before enrollment.

48 After intravitreal injection, bevacizumab can be detected in s

49 treal drug injection (3 eyes after the first intravitreal injection: bevacizumab in 1 and ranibizumab

50 ory of RD or retinal break, endophthalmitis, intravitreal injection, choroidal retinal vitreal biopsy

51 d Medicaid Services was used to identify all intravitreal injection claims and anti-VEGF drug claims

52 Data were searched for all intravitreal injections (Current Procedural Terminology

53 Intravitreal injections distributed more to the inner re

54 zumab to 0.5 mg ranibizumab given as monthly intravitreal injections during 6 months in patients with

55 rvice volume elasticity were nonsignificant: intravitreal injection elasticity, -0.75 (95% confidence

56 egeneration and diabetic retinopathy require intravitreal injections every 4-8 weeks.

57 anulomatous vasculitis were noted in 7 of 30 intravitreal injection eyes.

58 NPV (88.6%-100%) including billing codes for intravitreal injection, focal laser, panretinal photocoa

59 for 1 year, with a loading dose of 3 monthly intravitreal injections, followed by an as-needed regime

60 A total of 5 patients (2.2%) received intravitreal injections following funduscopic screening.

61 elivery may become a safe alternative to the intravitreal injection for chronic retinal diseases such

62 2, 2008 to June 30, 2013, a total of 316,576 intravitreal injections from 25 French ophthalmic center

63 dophthalmitis), our analysis involved 383810 intravitreal injections given to 58612 patients.

64 mber 2016, nonpriming the syringe before the intravitreal injection had a higher risk of intravitreal

65 systemic treatment only, regimens containing intravitreal injections had greater rates of retinitis p

66 preliminary efficacy of 125 mug ocriplasmin intravitreal injection in patients with focal vitreomacu

67 Eight weeks after single intravitreal injection in Royal College of Surgeons (RCS

68 e in transducing inner retinal neurons after intravitreal injection in several species.

69 luate the safety of pegaptanib sodium 0.3 mg intravitreal injection in the treatment of neovascular a

70 gression analysis, over the course of weekly intravitreal injections in retinoblastoma patients, for

71 The review assessed 4488 intravitreal injections in the 3-month period before (Ma

72 Intravitreal injections increased by 89 563%.

73 rs for PCR were age, sex, number of previous intravitreal injections, indication for intravitreal the

74 The incidence of endophthalmitis after intravitreal injection is low.

75 that anti-VEGF pharmacotherapy, delivered by intravitreal injection, is a safe and effective treatmen

76 uring cataract surgery in eyes with previous intravitreal injection (IVI).

77 Intravitreal injections (IVI) of anti-vascular endotheli

78 remarkable improvement was noticed after the intravitreal injection(IVI) of Ozurdex, consistent with

79 ious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothel

80 Use of fluoroquinolone drops after intravitreal injection leads to increased rates of resis

81 mab acquired from compounding pharmacies for intravitreal injection may cause infectious and noninfec

82 Intravitreal injections may be a precipitating factor fo

83 A history of intravitreal injections may be a risk factor for catarac

84 peated use of topical fluoroquinolones after intravitreal injections may have a detrimental effect on

85 gs were bleb associated (n = 17; 27%), after intravitreal injection (n = 16; 25%), and after cataract

86 us disease in zone II, were treated with one intravitreal injection of 0.03 ml ranibizumab.

87 The patient was treated with a single intravitreal injection of 0.05 ml/0.5 mg aflibercept.

88 erence tomography (SD OCT) received a single intravitreal injection of 0.3 mL 100% perfluoropropane (

89 One eye was randomized to receive an intravitreal injection of 0.5 mg bevacizumab; the fellow

90 42 eyes), 1 eye was randomized to receive an intravitreal injection of 0.5 mg bevacizumab; the fellow

91 A monthly intravitreal injection of 0.5 mg ranibizumab yields a du

92 Each eye received a single intravitreal injection of 0.5 mg ranibizumab.

93 Rbpms-positive cells was noted 1 week after intravitreal injection of 12, 30, and 120 nmol N-methyl-

94 Intravitreal injection of 2-ME (in the two concentration

95 ose of study was to evaluate the efficacy of intravitreal injection of 2-Methoxyestradiol (2-ME) nano

96 Intravitreal injection of 2-Methoxyestradiol nanoemulsio

97 Inner retinal edema was induced by intravitreal injection of 2.5 nmol N-methyl-D-aspartate

98 Intravitreal injection of 29D7 enhanced RGC survival but

99 s have highlighted the risks and benefits of intravitreal injection of a number of medications, the m

100 expression in the macaque inner retina after intravitreal injection of AAV vectors containing five di

101 The results in the macaque suggest that intravitreal injection of AAV2 would produce high levels

102 spective open-label, unilateral single-dose, intravitreal injection of AAV2(Y444,500,730F)-P1ND4v2 pe

103 a suprachoroidal injection of CLS-TA with an intravitreal injection of aflibercept (combination arm)

104 of aflibercept (combination arm) or only an intravitreal injection of aflibercept (monotherapy arm),

105 Intravitreal injection of aflibercept suppressed the aqu

106 Intravitreal injection of AGA per se in normal rats resu

107 Intravitreal injection of an Ad5 adenovirus expressing D

108 Intravitreal injection of an endothelial-specific IGFBP-

109 It was further demonstrated that intravitreal injection of an MCP-1-neutralizing antibody

110 nd phosphorescence emission was imaged after intravitreal injection of an oxygen-sensitive molecular

111 Intravitreal injection of Ang-2 in rats produced a signi

112 Transient elevation in IOP is common after intravitreal injection of anti-VEGF agents.

113 initial treatment was a vitreous culture and intravitreal injection of antibiotics in 28 of 36 patien

114 four disc areas, pars plana vitrectomy with intravitreal injection of antibiotics without retinectom

115 Intravitreal injection of autologous blood induced retin

116 Eyes were randomized to receive intravitreal injection of bevacizumab (1.25 mg; n = 182)

117 odds of developing endophthalmitis after an intravitreal injection of bevacizumab compared with rani

118 Direct intravitreal injection of bevacizumab has a more sustain

119 Initial treatment with either a single intravitreal injection of bevacizumab in off-label use (

120 VEGF and TNFalpha signaling was inhibited by intravitreal injection of bevacizumab or etanercept, res

121 ndividual from this data set who received an intravitreal injection of bevacizumab or ranibizumab (n=

122 us endophthalmitis cases occurring after the intravitreal injection of bevacizumab suggest that the v

123 outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab with fellow eyes t

124 Eyes were randomly assigned to receive an intravitreal injection of bevacizumab, 1.25 mg, or aflib

125 Initial management included cryotherapy, intravitreal injection of bevacizumab, plaque radiothera

126 s, presenting 1 to 6 days after receiving an intravitreal injection of bevacizumab.

127 Intravitreal injection of biodegradable nanoparticles (N

128 Intravitreal injection of C1-INH similarly decreased imp

129 study, retinal toxicity was determined after intravitreal injection of caspofungin in a mouse model t

130 A pars plana vitrectomy with intravitreal injection of ceftazidime (2 mg/0.1 ml) and

131 Intravitreal injection of ciliary neurotrophic factor in

132 Intravitreal injection of collagenase mimicked PK's effe

133 Eight eyes of 8 patients who received an intravitreal injection of compounded combined bevacizuma

134 port a fungal endophthalmitis outbreak after intravitreal injection of contaminated, compounded combi

135 were anesthetized and received a unilateral intravitreal injection of CtB.

136 Intravitreal injection of DAD restored retinal light res

137 C57BL/6J mice received an intravitreal injection of Edn2 or control vehicle to exa

138 rms in mice and found that both systemic and intravitreal injection of engineered AAV vectors resulte

139 avorable effects on DR were also achieved by intravitreal injection of fenofibrate or another specifi

140 Intravitreal injection of FH535 in swine also inhibited

141 In contrast, intravitreal injection of fluorescein targeted the vitre

142 terial in the eye over time as compared with intravitreal injection of fluorescein.

143 Following intravitreal injection of fluorescently labeled nanotube

144 nt by the injection of subretinal fluid, and intravitreal injection of green fluorescent protein-posi

145 increased total retinal Angptl4 protein, but intravitreal injection of GSK0660 had no effect.

146 Intravitreal injection of GW0742 significantly increased

147 Intravitreal injection of GW0742 significantly increased

148 Evaluation of safety found no toxicity after intravitreal injection of HDP-CDV up to 28 mug/eye.

149 Intravitreal injection of IGFBP-3-expressing plasmid int

150 In vivo, intravitreal injection of IGFBP-3NB reduced vascular lea

151 es by repressing inflammatory pathways using intravitreal injection of IL-17A mAbs.

152 Intravitreal injection of IL-4 and IL-10 ameliorated RPE

153 A single intravitreal injection of infliximab (1 mg/0.05 mL) was

154 Intravitreal injection of just 2% of the systemic dose o

155 Intravitreal injection of LeTx over a restricted time in

156 After intravitreal injection of LIF, we analyzed the expressio

157 In vivo, an intravitreal injection of Mab2F1 significantly reduced r

158 Trans-pars plana intravitreal injection of melphalan hydrochloride (40 mi

159 Intravitreal injection of membrane-permeable radical sca

160 Intravitreal injection of miR200-b DNA NPs significantly

161 Patients were to receive a single intravitreal injection of MP0112 at doses ranging from 0

162 After a single intravitreal injection of MP0112, the main outcomes were

163 Furthermore, a single intravitreal injection of MT-I/II after optic nerve crus

164 Excitotoxicity of the retina was induced by intravitreal injection of N-methyl-d-aspartate (NMDA) in

165 Furthermore, intravitreal injection of NAC effectively protected rabb

166 Intravitreal injection of neutralizing antibodies agains

167 A single intravitreal injection of neutralizing reagents for this

168 phase 3 clinical trials to compare a single intravitreal injection of ocriplasmin (125 mug) with a p

169 Patients were treated with a single intravitreal injection of Ocriplasmin (Jetrea, Thromboge

170 A single intravitreal injection of ocriplasmin 125 mug or placebo

171 In clinical practice, intravitreal injection of ocriplasmin achieved VMT relea

172 Intravitreal injection of Ocriplasmin resulted to be a s

173 If intravitreal injection of ocriplasmin was the primary pr

174 TG-MV-007, respectively) to receive a single intravitreal injection of ocriplasmin, 125 mug, or place

175 ptotic inner retinal neurons, resulting from intravitreal injection of ouabain, also exhibited increa

176 Mouse eyes either received intravitreal injection of PEDF, DAPT (a gamma-secretase

177 wild-type (WT) controls were administered an intravitreal injection of PGN (a metabolite of which is

178 tored under control conditions and following intravitreal injection of pharmacological agents.

179 ats and that the combination of diabetes and intravitreal injection of PK in rats induces retinal thi

180 Intravitreal injection of PK increased both acute RVP an

181 Intravitreal injection of PK increased retinal thickness

182 ment of bovine retinal endothelial cells and intravitreal injection of PKCbeta inhibitors as well as

183 Intravitreal injection of platelet-derived growth factor

184 lopment of CNV which was treated by a single intravitreal injection of ranibizumab (0.5 mg/0.05 mL).

185 A single intravitreal injection of ranibizumab had a long-lasting

186 Intravitreal injection of ranibizumab or bevacizumab.

187 All patients treated with intravitreal injection of ranibizumab, bevacizumab, or a

188 model was also used to assess the effects of intravitreal injection of recombinant opticin into eyes

189 Patients received a single intravitreal injection of RTH258 0.5 mg (n = 11), 3.0 mg

190 Intravitreal injection of saline has been shown potentia

191 eanwhile, the RGC count was higher following intravitreal injection of SCH442416 in the COH rats than

192 Intravitreal injection of selective A2A AR antagonist SC

193 Intravitreal injection of silicon-based QD seems to be s

194 a typical case of AZOOR, suggesting that the intravitreal injection of steroid may benefit in certain

195 of the retinal projections as revealed after intravitreal injection of the anterograde tracer cholera

196 In the OIR model, intravitreal injection of the regulated promoter at post

197 Intravitreal injection of the vitreolytic agent ocriplas

198 Intravitreal injection of this mutant caused a significa

199 r of matrix metalloproteinases-3 (TIMP3), or intravitreal injection of TIMP3 or of the EGFR inhibitor

200 xygen chamber at P12, they received a single intravitreal injection of TIMP3, erlotinib, or control.

201 We found that intravitreal injection of TLR2 agonist Pam3Cys and Staph

202 d 3. Attenuation of the ERG b-wave following intravitreal injection of TRPM1-positive MAR IgG into wi

203 At 24 weeks, monthly intravitreal injection of VEGF Trap-Eye 2 mg in eyes wit

204 After three intravitreal injections of 1.25 mg bevacizumab, her visi

205 C57BL/6, BALB/c, and BALB(gld) mice received intravitreal injections of 2,500 CFU of S. aureus (RN639

206 Intravitreal injections of 2.0 mg ranibizumab led to sta

207 ked criteria, for example, minimum number of intravitreal injections of a specific drug and visual ac

208 human clinical trials rely on subretinal or intravitreal injections of adeno-associated virus to del

209 Intravitreal injections of amikacin (0.4 mg/0.1 mL) were

210 was observed with ocular therapies including intravitreal injections of anti-vascular endothelial gro

211 incidence of presumed endophthalmitis after intravitreal injections of anti-vascular endothelial gro

212 All patients received at least 3 monthly intravitreal injections of anti-VEGF agents.

213 Intravitreal injections of anti-VEGF medications increas

214 ntified anti-VEGF treatment using claims for intravitreal injections of anti-VEGF medications with a

215 Vitreous cultures with intravitreal injections of antibiotics and pars plana vi

216 n intraocular pressure (IOP) associated with intravitreal injections of antivascular endothelial grow

217 al visual loss developed after they received intravitreal injections of autologous adipose tissue-der

218 Intravitreal injections of autologous blood, plasma kall

219 From a total of 96 eyes treated with intravitreal injections of bevacizumab (10.5 +/- 7.6 (me

220 -control study between patients who received intravitreal injections of bevacizumab as the sole treat

221 ort engorged vessel occlusion after repeated intravitreal injections of bevacizumab to treat the macu

222 All included patients had received intravitreal injections of bevacizumab, ranibizumab, or

223 Intravitreal injections of commonly used anti-VEGF intra

224 Both subcutaneous and intravitreal injections of drug-loaded microparticles in

225 -3 study, patients with DME received monthly intravitreal injections of either 0.5 or 2.0 mg ranibizu

226 Intravitreal injections of either PK or collagenase, but

227 Intravitreal injections of exogenous PK induced retinal

228 owering general retinal MMP activity through intravitreal injections of GM6001 after ONC strongly red

229 rm-field ERGs were recorded before and after intravitreal injections of L-AP4 (not APB) (2-amino-4-ph

230 lt zebrafish of both sexes were subjected to intravitreal injections of ouabain, which destroys the i

231 icipants were randomly assigned (1:1:1:1) to intravitreal injections of ranibizumab (0.5 mg) or bevac

232 Patients were randomized to receive intravitreal injections of ranibizumab 0.5 mg or 2.0 mg

233 ar age-related macular degeneration received intravitreal injections of ranibizumab or bevacizumab un

234 atment-naive DME were treated with 3 monthly intravitreal injections of ranibizumab or bevacizumab.

235 Eyes were treated with three intravitreal injections of ranibizumab, followed by PRN

236 ivery to the posterior eye segment relies on intravitreal injections of therapeutics.

237 Intravitreal injections of these peptides and PEDF in th

238 aiiensis developed in a series of eyes after intravitreal injections of triamcinolone obtained from a

239 d for 15 patients (n = 17 eyes) who received intravitreal injections of triamcinolone obtained from a

240 s is a notice to ophthalmologists performing intravitreal injections of triamcinolone or other medica

241 6.9%, refractory to laser grid treatment and intravitreal injections of triamcinolone, was selected t

242 Five patients were imaged before and after intravitreal injections of vascular endothelial growth f

243 Effects of intravitreal injections of VEGF and the VEGF inhibitor V

244 The treatment involves monthly repeated intravitreal injections of VEGF inhibitors.

245 Effects of intravitreal injections of VEGF-A, VEGF-E, PlGF-1, and V

246 ups and treated at postnatal day (P) 14 with intravitreal injections of Wnt-signaling modulators (res

247 intraocular therapies (ganciclovir implants, intravitreal injections) on ocular outcomes were evaluat

248 eovascular AMD diagnosis and mean numbers of intravitreal injections, ophthalmologist visits, and opt

249 Carcinine, administered by intravitreal injection or gavage, strongly protected mou

250 andomized 3:1 to receive 125 mug ocriplasmin intravitreal injection or sham injection.

251 y assigned to 0.4-mg, 1-mg, 3-mg PF-04523655 intravitreal injections or laser.

252 A single dose of SRT significantly reduces intravitreal injections over 2 years.

253 The cost estimate for intravitreal injections over a 6-month period was 11.7%

254 ti-VEGF therapy, calculated as the number of intravitreal injections per month, and central macular t

255 An audit of intravitreal injections performed by retinal specialists

256 Intravitreal injections play a critical role in daily op

257 es were surveyed regarding current anti-VEGF intravitreal injection protocols, including the anti-VEG

258 High variation was observed in intravitreal injection rates and in Medicare drug paymen

259 All patients who received subsequent intravitreal injections received PI prophylaxis without

260 The overall rate of intravitreal injection-related endophthalmitis is greate

261 outcomes in beneficiaries with a history of intravitreal injections relative to those without were c

262 3) higher than posterior subconjunctival and intravitreal injections, respectively.

263 A total of 792 intravitreal injection room surfaces were sampled (396 b

264 ing program reduced surface ATP bioburden in intravitreal injection rooms to less than clean benchmar

265 hich 1035 (1.64%) were in eyes with previous intravitreal injection(s).

266 Following intravitreal injection, the covalently loaded particles

267 metic Fab-PEG-Fab (FpFinfliximab) for direct intravitreal injection to assess whether such formulatio

268 ice-based MIVS, anti-VEGF, and dexamethasone intravitreal injections (triple therapy) for the treatme

269 re recommended in patients with a history of intravitreal injections undergoing cataract extraction.

270 We also evaluated the efficacy of intravitreal injection using a recently developed photor

271 Ocular surface preparation for intravitreal injection using povidone-iodine 5% alone in

272 The risk of endophthalmitis after intravitreal injection varied among agents that were use

273 rate of FFS Medicare beneficiaries receiving intravitreal injections varied widely by 7-fold across s

274 tinuous variable, the odds ratio for PCR per intravitreal injection was 1.04 (P = 0.016) after adjust

275 After logistic regression, prior intravitreal injection was associated with an increased

276 en topical antibiotics were prescribed after intravitreal injection was compared with a 9-month perio

277 The suitability for ocriplasmin intravitreal injection was determined according to the c

278 The mean number of intravitreal injections was 8.3 (range, 3-29 injections)

279 For each center, the number of intravitreal injections was determined using billing cod

280 Eyes that received intravitreal injection were also dilated at 24, 48, and

281 Relative proportions of the drugs used for intravitreal injections were calculated and frequencies

282 During the study period, a total of 117 171 intravitreal injections were performed (57 654 injection

283 ,714 anti-VEGF injections and 18 666 steroid intravitreal injections were performed and followed by 7

284 A total of 40 535 intravitreal injections were performed by 7 retinal spec

285 taract surgeon grade, and number of previous intravitreal injections were significant predictors of P

286 The safety and pharmacokinetics of HDP-CDV intravitreal injections were studied using New Zealand R

287 Intravitreal injections were the primary driver of growt

288 720 721 procedures [eg, surgery], and 45 416 intravitreal injections) were stored, including 81 274 o

289 udative form of the disease require repeated intravitreal injections which may be painful, are incomp

290 hthalmitis 41 to 97 days after receiving the intravitreal injection, which was prepared by the same c

291 ving anti-vascular endothelial growth factor intravitreal injections, which transiently increase IOP.

292 phthalmitis is a devastating complication of intravitreal injection with bevacizumab with a high rate

293 anesthetized Dutch-belted rabbits underwent intravitreal injection with I-124 bevacizumab, and three

294 Intravitreal injection with the gene therapy vector AAV2

295 l administration of 0.5 to 1.5 M MnCl(2) and intravitreal injections with 0.5 muL 100 mM and 2 muL 1

296 Thus, Phe-Phe nanotubes allow intravitreal injections with a small gauge needle and su

297 Patients were assigned randomly to receive intravitreal injections with either ranibizumab 0.5 mg o

298 generation who had received at least 3 prior intravitreal injections with use of postinjection topica

299 ti-vascular endothelial growth factor (VEGF) intravitreal injections without improvement.

300 The mean number of intravitreal injections without PI before the developmen